Cardiff Oncology Inc CRDF

NAS: CRDF | ISIN: US14147L1089 30/04/2025

2,740 USD (-1,44%)

(-1,44%) 30/04/2025

Grafiek Cardiff Oncology Inc

Grafiek Cardiff Oncology Inc

1 dag1d -1,44%
1 week1w -5,52%
1 maand1m -10,46%
3 maanden3m -31,67%
6 maanden6m -14,51%
1 jaar1j -35,22%
5 jaar5j 138,24%

Cardiff Oncology Inc in het nieuws

Toon enkel gratis nieuws

8 maart 2025 · Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge · Persbericht

17 januari 2024 · Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research · Persbericht

2 november 2023 · Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update · Persbericht

26 oktober 2023 · Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update · Persbericht

26 september 2023 · Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy · Persbericht

5 september 2023 · Cardiff Oncology to Present at Upcoming Investor Conferences in September · Persbericht

9 augustus 2023 · Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update · Persbericht

7 augustus 2023 · Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship · Persbericht

24 juli 2023 · Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

20 juni 2023 · Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

Profiel Cardiff Oncology Inc

Gezondheidszorg

Medische/verpleegkundige diensten

Productie van biologische producten

Website: cardiffoncology.com

Hoofdzetel: San Diego, California Verenigde Staten

CEO: Mark Erlander

Werknemers: 43

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe